Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Results: Baseline plasma HA was 4.4-fold higher (p < 0.05) in PDA vs healthy subjects. Disease status was a statistically significant covariate in NLME (?OBJ > 3.85), reducing inter-individual variability and supporting acceptance of the null hypothesis. Baseline plasma HA did not differ in subjects with HA high vs low tumors as defined by IHC. On average PEGPH20 dosing increased plasma HA concentration by 14 fold within 2 - 6 hours and 213 fold by 24 hours post dose. Conclusions: Baseline plasma HA concentrations were elevated in PDA subjects and increased dramatically over the first 24 hr post PEGPH20 dosing, which may be a useful pharmacodynamic marker for PEGPH20 activity.

http://abstracts.asco.org/176/AbstView_176_166182.html